Trial
NCT06158516
A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Changhai Hospital
Collaborators
—
Condition
Pancreatic Neuroendocrine Tumor
Intervention
Surufatinib
Why stopped
This investigator-initiated study closed to recruitment early due to slower-than-anticipated patient accrual.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-11